Theravance Biopharma (TBPH) Restructuring Costs (2021 - 2026)

Theravance Biopharma (TBPH) has 4 years of Restructuring Costs data on file, last reported at $2.6 million in Q1 2026.

• Restructuring Costs for Q1 2026 came in at $2.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (changed N/A YoY), and the FY2023 annual result was $2.7 million, down 78.63% from the prior year.
• Restructuring Costs improved to $2.6 million in Q1 2026 per TBPH's latest filing, from $1.2 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $33.0 million in Q3 2022 and troughed at $1.2 million in Q2 2023.
• A 3-year average of $8.4 million and a median of $2.8 million in 2022 frame the typical range for Restructuring Costs.
• The sharpest annual moves came in 2022 and 2023: Restructuring Costs jumped 114.29% in 2022, then sank 83.12% in 2023.
• A 3-year view of Restructuring Costs shows it stood at $33.0 million in 2022, then plunged by 96.46% to $1.2 million in 2023, then soared by 122.84% to $2.6 million in 2026.
• Business Quant data shows TBPH's Restructuring Costs at $2.6 million in Q1 2026, $1.2 million in Q2 2023, and $1.6 million in Q1 2023.